[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 304, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig M.B.A.", "age": 59, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1262378, "exercisedValue": 0, "unexercisedValue": 18056}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 713958, "exercisedValue": 0, "unexercisedValue": 5625}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 43, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 696350, "exercisedValue": 0, "unexercisedValue": 4219}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 68, "title": "Chief Technical Operations Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "LeAnne  Bloedon M.S.", "title": "VP & Head of Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John B. Harlow Jr.", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pinkosky", "title": "Vice President of Drug Discovery of Early Pre-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.7, "open": 3.86, "dayLow": 3.65, "dayHigh": 3.8899, "regularMarketPreviousClose": 3.7, "regularMarketOpen": 3.86, "regularMarketDayLow": 3.65, "regularMarketDayHigh": 3.8899, "payoutRatio": 0.0, "beta": 1.009, "forwardPE": 123.66667, "volume": 3598100, "regularMarketVolume": 3598100, "averageVolume": 6507652, "averageVolume10days": 4848170, "averageDailyVolume10Day": 4848170, "bid": 2.68, "ask": 4.0, "bidSize": 2, "askSize": 1, "marketCap": 879526848, "fiftyTwoWeekLow": 0.69, "fiftyTwoWeekHigh": 4.13, "allTimeHigh": 120.96, "allTimeLow": 0.69, "priceToSalesTrailing12Months": 2.8950663, "fiftyDayAverage": 3.3556, "twoHundredDayAverage": 2.04405, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1388064896, "profitMargins": -0.34835997, "floatShares": 234923762, "sharesOutstanding": 237069239, "sharesShort": 28827852, "sharesShortPriorMonth": 24958080, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.1216, "heldPercentInsiders": 0.00617, "heldPercentInstitutions": 0.47297, "shortRatio": 4.43, "shortPercentOfFloat": 0.1221, "impliedSharesOutstanding": 237069239, "bookValue": -2.197, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -105831000, "trailingEps": -0.54, "forwardEps": 0.03, "enterpriseToRevenue": 4.569, "enterpriseToEbitda": -47.416, "52WeekChange": 0.7209302, "SandP52WeekChange": 0.14561749, "quoteType": "EQUITY", "currentPrice": 3.71, "targetHighPrice": 16.0, "targetLowPrice": 1.72, "targetMeanPrice": 6.5025, "targetMedianPrice": 4.65, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 92447000, "totalCashPerShare": 0.39, "ebitda": -29274000, "totalDebt": 600985024, "quickRatio": 0.589, "currentRatio": 1.004, "totalRevenue": 303801984, "revenuePerShare": 1.538, "returnOnAssets": -0.05416, "grossProfits": 131898000, "freeCashflow": -78274248, "operatingCashflow": -93288000, "revenueGrowth": 0.691, "grossMargins": 0.43416, "ebitdaMargins": -0.09636, "operatingMargins": -0.11407, "financialCurrency": "USD", "symbol": "ESPR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.27027, "regularMarketPrice": 3.71, "marketState": "CLOSED", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "earningsTimestamp": 1762435800, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "earningsCallTimestampStart": 1762434000, "earningsCallTimestampEnd": 1762434000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.54, "epsForward": 0.03, "epsCurrentYear": -0.06714, "priceEpsCurrentYear": -55.25767, "fiftyDayAverageChange": 0.35439992, "fiftyDayAverageChangePercent": 0.10561447, "twoHundredDayAverageChange": 1.6659501, "twoHundredDayAverageChangePercent": 0.81502414, "priceToBook": -1.6886663, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1767400102, "regularMarketTime": 1767387601, "exchange": "NGM", "messageBoardId": "finmb_28236", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1372253400000, "postMarketChangePercent": 1.6172491, "postMarketPrice": 3.77, "postMarketChange": 0.059999943, "regularMarketChange": 0.00999999, "regularMarketDayRange": "3.65 - 3.8899", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 6507652, "fiftyTwoWeekLowChange": 3.02, "fiftyTwoWeekLowChangePercent": 4.3768115, "fiftyTwoWeekRange": "0.69 - 4.13", "fiftyTwoWeekHighChange": -0.42000008, "fiftyTwoWeekHighChangePercent": -0.101694934, "fiftyTwoWeekChangePercent": 72.093025, "displayName": "Esperion Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-03"}]